- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02851602
Phospholipid and Sphingolipid Composition of High-density Lipoproteins (HDL) in Obese Non-diabetic Patients With Metabolic Syndrome (SPHINGO)
HDL in obese non-diabetic patients show major alterations in their function and thus their cardio-protective effects. These alterations could be explained by the quantitative and qualitative anomalies in the phospholipids and sphingolipids in the HDL. These molecules play a major role in HDL function and probably present early modifications in obesity, even before the onset of glycaemia deregulation.
The aim of this study is to show the presence of qualitative and quantitative modifications of phospholipids and sphingolipids in HDL from obese patients compared with HDL from non-obese controls.
Studieoversikt
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Dijon, Frankrike, 21079
- CHU Dijon Bourgogne
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- aged > 18 years
- fasting glycaemia < 1.10 g/l
- waist circumference > 102 cm for men and 88 cm for women (criteria NCEP/ATP III)
- 2 criteria among the following 3 (NCEP/ATP III criteria for metabolic syndrome):
- triglyceridaemia ≥ 1.50 g/l
- HDL cholesterol < 0.40 g/l for men and 0.50 g/l for women
- arterial blood pressure ≥ 130/85 mmHg or treatment for arterial hypertension
- patients who have provided written consent INCLUSION CRITERIA FOR HEALTHY SUBJECTS
- age > 18 years
- fasting glycaemia < 1.10 g/l
- waist circumference < 102 cm for men and 88 cm for women
- triglyceridaemia < 1.50 g/l
- HDL cholesterol ≥ 0.40 g/l for men and 0.50 g/l for women
- Healthy subjects who have provided written consent
Exclusion Criteria:
- Persons without national health insurance cover
- Diabetes
- Diseases that interfere with lipoprotein metabolism (dysthyroidism not controlled with the treatment, kidney or liver disease)
- Treatments that interfere with lipoprotein metabolism (lipid-lowering agents, oestrogens, corticoids, retinoids, antiretroviral agents)
- Pregnancy/breast feeding
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: styre
|
|
|
Eksperimentell: Overvektige
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Difference in the mass percentages of total phospholipids + sphingolipids compared with the total HDL mass
Tidsramme: At inclusion
|
in patients with abdominal obesity without hyperglycaemia compared with healthy controls
|
At inclusion
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Difference in the percentage of each family of phospholipids or sphingolipids compared with total phospholipids + sphingolipids
Tidsramme: At inclusion
|
in patients with abdominal obesity but without hyperglycaemia compared with healthy controls
|
At inclusion
|
|
Difference in the percentage of each sub-family according to the nature of the fatty acids for phosphatidylcholines on the one hand and sphingomyelins on the other in patients
Tidsramme: At inclusion
|
with abdominal obesity but without hyperglycaemia compared with healthy control
|
At inclusion
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- VERGES 2013
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .